Document Detail


The Effect of Levothyroxine and Selenomethionine on Lymphocyte and Monocyte Cytokine Release in Women with Hashimoto's Thyroiditis.
MedLine Citation:
PMID:  21508145     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Context: No previous study determined monocyte- and lymphocyte-suppressing effects of levothyroxine and selenomethionine and assessed whether their coadministration is superior to treatment with only one of these drugs. Objective: Our objective was to compare the effect of levothyroxine and selenomethionine on monocyte and lymphocyte cytokine release and systemic inflammation in patients with Hashimoto's thyroiditis. Design, Setting, Participants, and Intervention: We conducted a randomized clinical trial involving a group of 170 ambulatory euthyroid women with recently diagnosed and previously untreated Hashimoto's thyroiditis and 41 matched healthy subjects. Participants were randomized in a double-blind fashion to receive a 6-month treatment with levothyroxine, selenomethionine, levothyroxine plus selenomethionine, or placebo. One hundred sixty-five patients completed the study. Main Outcome Measures: Monocyte and lymphocyte release of proinflammatory cytokines and plasma levels of C-reactive protein (CRP) were assessed. Results: Compared with the control subjects, monocytes and lymphocytes of Hashimoto's thyroiditis patients released greater amounts of all cytokines studied. Levothyroxine reduced monocyte release of TNF-α, IL-1β, IL-6, and monocyte chemoattractant protein-1, whereas selenomethionine inhibited lymphocyte release of IL-2, interferon-γ, and TNF-α, which was accompanied by a reduction in plasma CRP levels. The decrease in cytokine release and in plasma CRP levels was strongest when both drugs were given together. Conclusions: Despite affecting different types of inflammatory cells, levothyroxine and selenomethionine exhibit a similar systemic antiinflammatory effect in euthyroid females with Hashimoto's thyroiditis. This action, which correlates with a reduction in thyroid peroxidase antibody titers, may be associated with clinical benefits in the prevention and management of Hashimoto's thyroiditis, particularly in subjects receiving both agents.
Authors:
Robert Krysiak; Boguslaw Okopien
Related Documents :
20818145 - [recent advances in the roles of dendritic cells on contact dermatitis].
16788625 - The role of epidermal cytokines in inflammatory skin diseases.
12390445 - Hypoproteinemia in severe childhood atopic dermatitis: a serious complication.
11137395 - T cells, immunosurveillance, and cutaneous immunity.
10972965 - Fas (cd95/apo-1) plays a role in the pathophysiology of focal cerebral ischemia.
21269535 - 1-phenyl-6,7-dihydroxy-isochroman suppresses lipopolysaccharide-induced pro-inflammator...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-20
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  -     ISSN:  1945-7197     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, PL 40-752 Katowice, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Novel Approach to the Detection of Acromegaly: Accuracy of Diagnosis by Automatic Face Classificat...
Next Document:  Mineral Metabolism Markers and the Long-Term Risk of Hip Fracture: The Cardiovascular Health Study.